Keywords: Nycomed, Instanyl, European Commission, Brakthrough cancer pain, Single-dose, Takeda

European clearance for Nycomed's Instanyl single-dose nasal spray

Article | 05 July 2011

Print This

Independent Swiss drugmaker Nycomed, which is the subject of a $13.9 billion takeover by Japan’s Takeda Pharmaceuticals (TYO: 4502), says ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in